ライフサイエンスコーパス: positron emission tomography

1 trial (Prediction of Arrhythmic Events with Positron Emission Tomography).

2 n were measured using 18F-fluorodeoxyglucose positron emission tomography.

3 scular magnetic resonance, and (11)C-acetate positron emission tomography.

4 e to that achieved by expert assessment with positron emission tomography.

5 ostic index, and CFR was quantified by using positron emission tomography.

6 [(18)F]fluorodeoxyglucose ([(18)F]FDG) with positron emission tomography.

7 in the murine brain for up to one week using positron emission tomography.

8 preparation of potential tracers for use in positron emission tomography.

9 new radiotracers for molecular imaging with positron emission tomography.

10 metabolic response by 18F-fluorodeoxyglucose positron-emission tomography.

11 s of 1344 pixel range of perfusion in paired positron emission tomographies.

12 Combined oxygen 15-labeled positron emission tomography (15O PET) and brain tissue

13 ion delivered to the liver utilizing an oral positron emission tomography (18) F-isotopologue validat

14 n was assessed by MRI and fludeoxyglucose-18 positron emission tomography ((18)FDG-PET).

15 using fluorine-18-labeled fluorodeoxyglucose positron emission tomography ([(18)F]FDG PET), [(18)F]FD

16 Whole-body (18)F-fluodeoxyglucose positron emission tomography ([(18)F]FDG-PET) imaging ha

17 f 10 minutes between (18)F-FCH injection and positron emission tomography acquisition is appropriate

18 arbon 11-labeled Pittsburgh Compound B (PiB) positron emission tomography after long-term prospective

19 3) or elevated (n = 202) brain amyloid using positron emission tomography amyloid imaging or a cerebr

20 ents received a second Pittsburgh compound B positron emission tomography analysis.

21 inical evaluation and imaging at enrollment (positron emission tomography and 2-dimensional echo).

22 ers, and 18 nonsmokers who were scanned with positron emission tomography and [(11)C]raclopride, afte

23 erebral glucose metabolism was assessed with positron emission tomography and [F-18]fluorodeoxyglucos

24 14 healthy individuals using [(11)C]-acetate positron emission tomography and cardiovascular magnetic

25 disease, thanks to advances in MRI, amyloid positron emission tomography and cerebrospinal fluid bio

26 nt for pathogenesis and treatment.IMPORTANCE Positron emission tomography and computed tomography (PE

27 luorodeoxyglucose [FDG] avidity) measured by positron emission tomography and computed tomography at

28 Positron emission tomography and computed tomography ima

29 essment in patients with lymphoma, including positron emission tomography and computed tomography sca

30 stic accuracy of Fluor-18-fluorodeoxyglucose positron emission tomography and computed tomography, la

31 d 77 years underwent 11C-(R)PK11195, 11C-PIB positron emission tomography and magnetic resonance imag

32 d the activity of the PSMA-PI3K axis through positron emission tomography and magnetic resonance imag

33 tients underwent (11)C-Pittsburgh compound B positron emission tomography and magnetic resonance imag

34 MENT We here show that combined simultaneous positron emission tomography and magnetic resonance imag

35 Hybrid positron emission tomography and magnetic resonance in t

36 20 min, and 50 min with (15)O-water by using positron emission tomography and MRI.

37 A meta-analysis of 142 positron emission tomography and single photon emission

38 ects and 23 healthy controls participated in positron emission tomography and structural magnetic res

39 agnetic resonance imaging, amyloid (11C-PiB) positron emission tomography and tau (18F-AV-1451) posit

40 he results of their florbetapir F-18 (Abeta) positron emission tomography and their Alzheimer disease

41 ndication of neuroinflammation in vivo using positron emission tomography and TSPO-specific radioliga

42 (18)F-fluorodeoxyglucose-positron emission tomography and ultrasmall superparamag

43 ter stress testing with myocardial perfusion positron emission tomography and with left ventricular e

44 Staging used positron emission tomography and/or computed tomography.

45 ned by fluorodeoxyglucose F 18 [FDG]-labeled positron emission tomography and/or hippocampal volume [

46 amyloid burden (measured by florbetapir F-18 positron emission tomography) and cognitive performance

47 on emission tomography and tau (18F-AV-1451) positron emission tomography, and episodic and semantic

48 beta-cells in pigs and nonhuman primates by positron emission tomography as well as in immunodeficie

49 d potentially have changed 332 of 1732 (19%) positron emission tomographies at low-risk physiological

50 Finally, the authors review positron emission tomography-based imaging techniques to

51 Positron emission tomography-based regional measures of

52 amyloid-beta plaques measured as florbetapir positron emission tomography binding antecedent to 18F-A

53 ng cerebrospinal fluid (CSF) or imaging (tau positron emission tomography) biomarkers for Alzheimer d

54 dementia) and 12 healthy controls underwent positron emission tomography brain imaging with [(18)F]A

55 tomography, magnetic resonance imaging, and positron emission tomography can be used to assess pulmo

56 Positron emission tomography can be useful to identify a

57 rticipants underwent 18-F Fluorodeoxyglucose Positron Emission Tomography Computed Tomography (18-FDG

58 cted by (18)F-fluorodeoxyglucose ((18)F-FDG) positron emission tomography computed tomography (PET/CT

59 Purpose Magnetic resonance imaging (MRI) and positron emission tomography-computed tomography (PET-CT

60 ained from baseline (18)F-fluorodeoxyglucose positron emission tomography-computed tomography (PET-CT

61 l present the analyses of centrally reviewed positron emission tomography-computed tomography (PET-CT

62 TV0 was measured by (18)F-fluorodeoxyglucose-positron emission tomography-computed tomography in 108

63 cation, adenocarcinoma histology, and higher positron emission tomography-computed tomography N stage

64 r extracranial metastatic lesions on choline positron emission tomography-computed tomography, and se

65 Vascular inflammation was assessed with positron emission tomography-computed tomography.

66 stenosis underwent (18)F-fluorodeoxyglucose-positron emission tomography/computed tomographic imagin

67 med to determine whether 18F-fludeoxyglucose-positron emission tomography/computed tomography (FDG-PE

68 ng of surveillance [(18)F]fluorodeoxyglucose-positron emission tomography/computed tomography (FDG-PE

69 (18)F-Fluorodeoxyglucose (FDG) positron emission tomography/computed tomography (PET/CT

70 ings from dual-energy spectral CT(DEsCT) and positron emission tomography/computed tomography (PET/CT

71 Staging with positron emission tomography/computed tomography (PET/CT

72 Previously, we demonstrated that positron emission tomography/computed tomography (PET/CT

73 duals who underwent (18)F-fluorodeoxyglucose positron emission tomography/computed tomography imaging

74 ascular inflammation by 18fluorodeoxyglucose positron emission tomography/computed tomography in vivo

75 ned in a single hybrid imaging session using positron emission tomography/computed tomography or sing

76 rom 31 patients and results of early interim positron emission tomography/computed tomography scans i

77 ascular inflammation by 18fluorodeoxyglucose positron emission tomography/computed tomography, with g

78 -to-background ratio by 18fluorodeoxyglucose positron emission tomography/computed tomography.

79 ar inflammation led to the increasing use of positron emission tomography/computed tomography.

80 Systemic venous sampling and positron emission tomography confirm uptake of glucose a

81 s an insufficient explanation of 18F-AV-1451 positron emission tomography data in vivo, at least in t

82 Fluorodopa positron emission tomography demonstrated significant in

83 and insulin sensitivity were measured using positron emission tomography during an isoglycemic clamp

84 ose concentrations) with 1-[(11)C]-d-glucose positron emission tomography during hyperinsulinemic glu

85 ical assessment, brain 18-fluorodeoxyglucose positron emission tomography, electroneurography, and EL

86 ontribute to disease profiles of 18F-AV-1451 positron emission tomography, especially in primary tauo

87 (18)F-Fluorodeoxyglucose-positron emission tomography (FDG-PET) has become a cent

88 l that used early interim fluorodeoxyglucose positron emission tomography (FDG-PET) imaging to determ

89 t and high-resolution (18)fluorodeoxyglucose positron emission tomography (FDG-PET) imaging to unders

90 ce imaging (MRI) and (18)F-fluordeoxyglucose positron emission tomography (FDG-PET).

91 t-Enhanced MRI (DCE-MRI) and Fludeoxyglucose Positron Emission Tomography(FDG-PET).

92 together to enable simultaneous tetramodal (positron emission tomography/fluorescence/Cerenkov lumin

93 nts underwent magnetic resonance imaging and positron emission tomography for amyloid-beta ((11) C-Pi

94 healthy control subjects had 11C-(R)-PK11195 positron emission tomography for comparison.

95 pir F 18 (previously known as AV 1451, T807) positron emission tomography (FTP-PET) imaging for tau a

96 erebral Abeta on Pittsburgh Compound B (PiB) positron emission tomography, gait speed over 4.57 m (15

97 the clinical use of RHL30 in the context of positron emission tomography-guided response assessment

98 New radioligands for positron emission tomography have generated considerable

99 Positron emission tomography image analysis was complete

100 aphy with iron oxide particles, and targeted positron emission tomography imaging are currently under

101 Dynamic positron emission tomography imaging demonstrated that a

102 New recommendations for positron emission tomography imaging for the evaluation

103 nflammation, were measured with [(11)C]PBR28 positron emission tomography imaging in 15 healthy contr

104 Positron emission tomography imaging of mice bearing PC3

105 Positron emission tomography imaging reveals neuroinflam

106 We assessed the radiotracer 18F-AV-1451 with positron emission tomography imaging to compare the dist

107 had available plasma total tau levels, Abeta positron emission tomography imaging, and a complete neu

108 l and structural magnetic resonance imaging, positron emission tomography imaging, and behavioral dat

109 structural MRI, [(18)F]flutemetamol amyloid positron emission tomography imaging, apolipoprotein E g

110 d quantitative techniques, including in vivo positron emission tomography imaging, gamma counting, an

111 sessments, seizures, corticosteroid use, and positron emission tomography imaging.

112 We show that immuno-positron emission tomography (immuno-PET) can visualize

113 onic uptake of [(18)F]-fluorodeoxyglucose by positron emission tomography in Hdc(-/-) mice.

114 etic resonance imaging and spectroscopy, and positron emission tomography in these areas and discusse

115 We suggest that 18F-AV-1451 positron emission tomography is a useful biomarker to as

116 Although, currently positron emission tomography is the most commonly used t

117 Here we compared binding of tau positron emission tomography ligands, PBB3 and AV-1451,

118 take with [(18) F]2-fluoro-2-deoxy-D-glucose/positron emission tomography, lipolysis (RaGly) with [U-

119 Using positron emission tomography, magnetic resonance spectro

120 Positron emission tomography/magnetic resonance imaging

121 netic melanin nanoparticles is developed for positron-emission tomography/magnetic resonance/photoaco

122 ing fundamentals necessary to understand how positron emission tomography makes robust, quantitative

123 e in PCC fludeoxyglucose F 18 ([(18) F] FDG) positron emission tomography measured in Alzheimer's Dis

124 pleasant, and neutral images), and underwent positron emission tomography measurements of dopamine D2

125 latform for magnetic resonance/photoacoustic/positron emission tomography multimodal imaging and ligh

126 t state-of-the-art hardware and software for positron emission tomography myocardial perfusion imagin

127 lume of denervated myocardium (defect of the positron emission tomography norepinephrine analog (11)C

128 [(11)C]5-hydroxy-tryptophan ([(11)C]5-HTP) positron emission tomography of the pancreas has been sh

129 etic resonance imaging, nuclear imaging, and positron emission tomography) performed on an outpatient

130 Positron emission tomography (PET) -computed tomography

131 Combined positron emission tomography (PET) and computed tomograp

132 single-photon emission tomography (SPECT) or positron emission tomography (PET) and coronary computed

133 hcare, Shanghai, China) followed by combined positron emission tomography (PET) and CT (hereafter, PE

134 (18)F-Fluorodeoxyglucose (FDG)-positron emission tomography (PET) and diffusion-weighte

135 y menstruating, asymptomatic women completed positron emission tomography (PET) and functional magnet

136 fluorine 18 ((18)F) fluorodeoxyglucose (FDG) positron emission tomography (PET) and hyperpolarized ca

137 18 ((18)F) fluorodeoxyglucose (FDG) combined positron emission tomography (PET) and magnetic resonanc

138 h-resolution neuroimaging data consisting of positron emission tomography (PET) and magnetic resonanc

139 Nevertheless, studies using positron emission tomography (PET) and radioligands for

140 vity at fluorine 18 fluorodeoxyglucose (FDG) positron emission tomography (PET) and survival in patie

141 22 healthy recreationally active males using positron emission tomography (PET) and the MOR-selective

142 is to synthesise current evidence on amyloid-positron emission tomography (PET) burden and presumed p

143 racy of fluorine 18 fluorodeoxyglucose (FDG) positron emission tomography (PET) combined with diagnos

144 d mass spectrometric detection to quantify a positron emission tomography (PET) detection tracer for

145 fluorine 18 ((18)F) fluorodeoxyglucose (FDG) positron emission tomography (PET) has added value over

146 Dynamic positron emission tomography (PET) images were acquired

147 BACKGROUND AND Amyloid-positron emission tomography (PET) imaging (API) detects

148 Positron emission tomography (PET) imaging agents that d

149 Positron Emission Tomography (PET) imaging allows the es

150 ing (FL) and photodynamic therapy (PDT) with positron emission tomography (PET) imaging and internal

151 Amyloid positron emission tomography (PET) imaging is a valuable

152 exploited the potential targeting of TF for positron emission tomography (PET) imaging of pancreatic

153 Over the past years, positron emission tomography (PET) imaging studies have

154 Here we describe positron emission tomography (PET) imaging with (18)F-Ma

155 Positron emission tomography (PET) imaging with radiotra

156 ized male nonhuman primates (n = 3), we used positron emission tomography (PET) imaging with the radi

157 employed in the realm of nanoparticle-based positron emission tomography (PET) imaging, whereas its

158 g, or synthetic organic molecule for in vivo positron emission tomography (PET) imaging.

159 ased attenuation correction (ATAC) for brain positron emission tomography (PET) in an integrated time

160 Use of [(18)F]FDG-positron emission tomography (PET) in clinical breast ca

161 surgery on the human brain immune system by positron emission tomography (PET) in relation to blood

162 Positron emission tomography (PET) is a powerful analyti

163 Here, we show that positron emission tomography (PET) is advantageous for d

164 Positron emission tomography (PET) is an important drive

165 18-Fluorodeoxyglucose positron emission tomography (PET) is commonly utilized

166 tem (CNS) disorders, we sought to identify a positron emission tomography (PET) ligand to enable targ

167 isease (AD) and can be detected in vivo with positron emission tomography (PET) ligands.

168 ed that fluorine 18 fluorodeoxyglucose (FDG) positron emission tomography (PET) may detect the inflam

169 tional magnetic resonance imaging (fMRI) and positron emission tomography (PET) multimodal imaging wi

170 DPGM) is developed for MR/photoacoustic (PA)/positron emission tomography (PET) multimodal imaging-gu

171 Here we report a non-invasive quantitative positron emission tomography (PET) nanoreporter technolo

172 The method uses positron emission tomography (PET) of [(11)C]yohimbine b

173 Positron emission tomography (PET) offers superior contr

174 Here, we characterize a positron emission tomography (PET) probe for imaging DIP

175 by analyzing motor defects and binding of a positron emission tomography (PET) radioligand to the ve

176 ation is possible with the recent advance in positron emission tomography (PET) radioligands that bin

177 ch toward the radiosynthesis of heterocyclic positron emission tomography (PET) radioligands using th

178 Radiolabeling with long-lived positron emission tomography (PET) radionuclides, such a

179 (CCR2)-binding peptide adapted for use as a positron emission tomography (PET) radiotracer for nonin

180 While the benefits of MRI are many, positron emission tomography (PET) radiotracers are stil

181 A positron emission tomography (PET) scan confirmed the lu

182 Early response evaluation with positron emission tomography (PET) scan may improve sele

183 Ten subjects also completed a positron emission tomography (PET) scan to quantify DRN

184 nonsmokers participated in two [(11)C]ABP688 positron emission tomography (PET) scans on the same day

185 had magnetic resonance imaging (MRI) scans, positron emission tomography (PET) scans with carbon 11-

186 Previous positron emission tomography (PET) studies targeting the

187 ur objective was to determine the pattern of positron emission tomography (PET) tau tracer AV-1451 up

188 racer [(11)C]DAA1106 (a ligand for TSPO) and positron emission tomography (PET) to determine the effe

189 a radioligand that binds to the mGluR5, and positron emission tomography (PET) to quantify in vivo m

190 calisation and magnitude of the presumed tau Positron Emission Tomography (PET) tracer [(18)F]Flortau

191 Recent studies have shown that positron emission tomography (PET) tracer AV-1451 exhibi

192 individuals: (1) Tau, detected with a novel positron emission tomography (PET) tracer known as (18)F

193 Consequently, positron emission tomography (PET) tracers addressing tr

194 )-3 ([(11)C]-(R)-IPMICF16), a first-in-class positron emission tomography (PET) TrkB/C-targeting radi

195 They came to an academic research center for positron emission tomography (PET) using [(18)F]fallypri

196 duced D2R internalization can be imaged with positron emission tomography (PET) using D2R radiotracer

197 Positron emission tomography (PET) using radiolabeled li

198 ents of the New York metropolitan area using Positron Emission Tomography (PET) with [(11)C]racloprid

199 n of dopamine to value-based attention using positron emission tomography (PET) with [(11)C]racloprid

200 Purpose To demonstrate that positron emission tomography (PET) with fluorine 18 ((18

201 d tumor cytopenia on repeat (68)Ga-DOTA-TATE positron emission tomography (PET) within 6 months, sugg

202 d included magnetic resonance imaging (MRI), positron emission tomography (PET), and single-photon em

203 sease (PD) with 18F-fluorodeoxyglucose (FDG) positron emission tomography (PET), and their associatio

204 Radiocaine, an F-18 radiotracer for positron emission tomography (PET), is the first SCN5A i

205 nitive continuum aged >60 years with amyloid positron emission tomography (PET), tau PET, and magneti

206 g a combination of functional MRI (fMRI) and positron emission tomography (PET), we investigated whet

207 ANCE STATEMENT: We present a high-resolution positron emission tomography (PET)- and magnetic resonan

208 In our phase 2 study of positron emission tomography (PET)-adapted salvage thera

209 stine, prednisone (R-CHOP14) induction and a positron emission tomography (PET)-driven ASCT or standa

210 yloid deposition, measured using florbetapir positron emission tomography (PET).

211 (sr39tk) reporter gene for cell detection by positron emission tomography (PET).

212 entual application in molecular imaging with positron emission tomography (PET).

213 , a dopamine D2/D3 receptor radiotracer, and positron emission tomography (PET).

214 ton emission computed tomography (SPECT) and positron emission tomography (PET).

215 lthy comparison subjects using [(11)C]IMA107 positron emission tomography (PET).

216 ivity was then quantified with [(18)F]-FDOPA positron emission tomography (PET).

217 cularly well suited for molecular imaging by positron emission tomography (PET).

218 -L1 VHH) to track PD-L1 expression by immuno-positron emission tomography (PET).

219 tion and whole-body dosimetry assessments by positron emission tomography (PET).

220 A positron emission tomography (PET)/ computed tomography

221 Purpose [(18)F]Sodium fluoride (NaF) positron emission tomography (PET)/computed tomography (

222 Purpose To assess the accuracy of staging positron emission tomography (PET)/computed tomography (

223 time using a combination of autoradiography, positron emission tomography (PET)/computed tomography (

224 eath hold (DIBH) in fluorodeoxyglucose (FDG) positron emission tomography (PET)/computed tomography (

225 In this report, a case of fire in a positron emission tomography (PET)/magnetic resonance (M

226 Materials and Methods An integrated positron emission tomography (PET)/magnetic resonance (M

227 e of flourine 18 ((18)F) fluorocholine (FCH) positron emission tomography (PET)/magnetic resonance (M

228 Purpose To develop a positron emission tomography (PET)/magnetic resonance (M

229 correction (AC) (termed deep MRAC) in brain positron emission tomography (PET)/MR imaging.

230 New radiolabeled probes for positron-emission tomography (PET) are providing an ever

231 ecombinant cellular systems, and critically, positron-emission-tomography (PET) studies with a specif

232 For amyloid positron emission tomography positive (Abeta+) subjects,

233 Here, we report the development of a positron emission tomography probe for live bacterial in

234 D2/3 agonist positron emission tomography radiotracer [(11)C]N-propyl

235 id (defined by cerebrospinal fluid assays or positron emission tomography regional summaries) can be

236 ated variability; and (iii) this 18F-AV-1451 positron emission tomography retention pattern significa

237 We found that: (i) 18F-AV-1451 positron emission tomography retention was differentiall

238 ed with age, and cross-sectional florbetapir positron emission tomography retention, but not with yea

239 t increased annualized change in florbetapir positron emission tomography retention.

240 11C-(R)-PK11195 positron emission tomography reveals increased inflammat

241 sion phenotyping approaches using (11)C with positron emission tomography, root autoradiography, and

242 Investigations at progression included positron emission tomography scan and biopsy.

243 dard for reporting the results of an amyloid positron emission tomography scan is to assign a dichoto

244 A positron emission tomography scan revealed bilateral cer

245 tently associated with an Abeta+ florbetapir positron emission tomography scan, not all Abeta+ subjec

246 = 306) and (18) fluorodeoxyglucose (n = 305) positron emission tomography scanning to assess amyloid

247 Positron emission tomography scanning with the transloca

248 F]fluoro-levo-dihydroxyphenylalanine dynamic positron emission tomography scans and striatal regions

249 resonance imaging and Pittsburgh compound B-positron emission tomography scans enrolled in the Mayo

250 3)I-MIBG scans, or [(18)F]fluorodeoxyglucose-positron emission tomography scans for MIBG-nonavid dise

251 eferred for rest/stress myocardial perfusion positron emission tomography scans from January 2006 to

252 ional resting-state (18)F-fluorodeoxyglucose positron emission tomography scans from VPA-exposed and

253 ne (MIBG) scans or [(18)F]fluorodeoxyglucose-positron emission tomography scans if the tumor is MIBG

254 atients were evaluated by fluorodeoxyglucose-positron emission tomography scans performed at baseline

255 DS AND In 127 volunteers, serial rest-stress positron emission tomography scans using rubidium-82 wit

256 Positron emission tomography scans were recommended befo

257 D and 12 healthy controls (HC) completed two positron emission tomography scans with [(11)C]-(+)-PHNO

258 tomography binding antecedent to 18F-AV-1451 positron emission tomography scans, and to what extent t

259 betapir retention, antecedent to 18F-AV-1451 positron emission tomography scans, in the parieto-tempo

260 information that could be available from tau positron-emission tomography scans and its use to determ

261 [(18)F]Fludeoxyglucose positron emission tomography showed increased myocardial

262 on between 18 kDa translocator protein brain positron emission tomography signal, which arises largel

263 years), response (PR v CR) after R-CHOP, and positron emission tomography status at assignment (negat

264 We used [(18)F]AV-1451 and [(11)C]PiB positron emission tomography, structural MRI, and neurop

265 usion, this is one of the first longitudinal positron emission tomography studies evaluating longitud

266 Positron emission tomography studies report either no di

267 e disorder (MDD), highlighting insights from positron emission tomography studies.

268 study and invited these individuals back for positron emission tomography study with [(18)F]-fluorode

269 imaging via photoacoustic, fluorescence, and positron emission tomography techniques.

270 We used [(11)C](R)-PK11195 positron emission tomography to compare TSPO availabilit

271 ulti-session [(15)O]-water and [(18)F]-FDOPA positron emission tomography to determine striatal blood

272 fluorodihydroxyphenyl-l-alanine ([18F]-DOPA) positron emission tomography to examine dopamine synthes

273 Here we used positron emission tomography to investigate whether feed

274 hy age-matched control individuals underwent positron emission tomography to measure cerebral metabol

275 Here, we used [(11)C]NOP-1A and positron emission tomography to measure the in vivo bind

276 We used in vivo positron emission tomography to test whether feeding tri

277 labeled with fluorine-18 ((18)F) are used in positron emission tomography to visualize, characterize

278 n tau tangle accumulation (measured with the positron emission tomography tracer 18F-AV-1451) associa

279 The advent of tau-targeted positron emission tomography tracers such as flortaucipi

280 evelopment of tools such as radioligands and positron emission tomography tracers that are not curren

281 Using tau-specific and Abeta-specific positron emission tomography tracers, we show that in vi

282 brain amyloid burden, as detected by amyloid positron emission tomography using 11C-Pittsburgh B comp

283 ith [(11)C]carfentanil and [(18)F]fluorodopa positron emission tomography using a high-resolution sca

284 x-matched control subjects had (18)F-AV-1451 positron emission tomography using a Siemens high-resolu

285 We acquired positron emission tomography using F18 flortaucipir (tau

286 nonoffenders were included and examined with positron emission tomography, using the radioligand [(11

287 1C-Pittsburgh compound B and 11C-(R)-PK11195 positron emission tomography was used to determine the a

288 [(18)F]CPFPX positron emission tomography was used to quantify A1AR a

289 Positron emission tomography was used to visualize neuro

290 Positron emission tomography was used with [(18)F]fallyp

291 glucose uptake, assessed through noninvasive positron emission tomography, was an effective predictiv

292 on-human primates and in human studies using positron emission tomography were not consistent.

293 dy, flortaucipir tau and florbetapir amyloid positron emission tomography were obtained for 217 subje

294 perfusion and coronary flow reserve (CFR) by positron emission tomography, where submaximal stress pr

295 Positron emission tomography with 18F-florbetapir and fl

296 f functional SGLT2 proteins in rodents using positron emission tomography with 4-[(18)F]fluoro-dapagl

297 iatal D2R binding potential (D2R BPND) using positron emission tomography with a D2R-selective radiol

298 (68)Gallium-DOTATATE positron emission tomography with computed tomography ((

299 e acquired in 14 long-term ex-smokers, using positron emission tomography with radiolabeled [11C]ABP6

300 onal neuroimaging ([(18)F]fluorodeoxyglucose positron emission tomography) with a fear-regulating ext